Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.

ABSTRACT:

Background

Afatinib, an irreversible pan-ERBB family inhibitor, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) patients with uncommon EGFR activating mutations. However, besides the acquisition of the secondary T790M mutation, other resistance mechanisms to afatinib remain to be explored.

Materials and methods

This study retrospectively included 37 NSCLC patients harboring either EGFR or ERBB2 activating mutations, who had received afatinib as first-line treatment. Targeted next-generation sequencing data on the baseline and post-progression samples were subjected to analysis. Comparative analyses of clinical parameters and genomic features were performed.

Results

Overall, the progression-free survival of the EGFR-mutated patients on first-l

SUBMITTER: Lin F 

PROVIDER: S-EPMC12639536 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature